SAN DIEGO, Feb. 3, 2021 /PRNewswire/ — ViaCyte, Inc., a clinical-stage regenerative medicine company, today announced that the first type 1 diabetes (T1D) patients have been implanted in a Phase 2 ...
TORONTO, ON--(Marketwired - July 29, 2015) - ViaCyte, Inc. announced the opening of a second site in its Phase 1/2 trial called STEP ONE, or Safety, Tolerability and Efficacy of VC-01™ Combination ...
NEW YORK, Dec. 13, 2011 /PRNewswire-USNewswire/ -- JDRF announced today its support of a pioneering diabetes research program that is developing a first-of-its-kind cell therapy for type 1 diabetes ...
ViaCyte, Inc., a clinical stage regenerative medicine company, and W. L. Gore & Associates, Inc. ("Gore"), a materials science company with expertise in medical device and drug delivery technologies, ...
JDRF, a global organization focused on type 1 diabetes (T1D) research, and the California Institute for Regenerative Medicine (CIRM) agreed to provide additional funding for the development of a novel ...
SAN DIEGO, Aug. 8, 2014 -- ViaCyte, Inc., a privately held regenerative medicine company developing a stem cell-derived islet replacement therapy for the treatment of diabetes, announced today that it ...
ViaCyte and Janssen Biotech have entered Phase I/Phase II clinical trials for VC-01, a candidate treatment for the treatment of type 1 diabetes. ViaCyte a privately held regenerative medicine company, ...
A century after researchers from the University of Toronto discovered the hormone as a treatment for diabetes in humans, insulin—and recombinant DNA versions brought to market in the past four decades ...
SAN DIEGO -- ViaCyte, Inc., a privately held regenerative medicine company announced today that it has entered into a Rights Agreement with Janssen Research & Development LLC (Janssen), one of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results